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Abstract Hyperlipidemia is associated with an increased
risk of cardiovascular events; reducing low-density lipo-
protein cholesterol (LDL-C), the primary target for cho-
lesterol-lowering therapy, lowers the risk for such events.
Although bile acid sequestrants were the first class of drugs
to show a mortality benefit related to LDL-C lowering,
statins are now considered first-line pharmacological ther-
apy for reducing LDL-C levels because of their potency
and their remarkable record of successful outcomes studies.
Nevertheless, a substantial proportion of patients do not
achieve LDL-C goals with statin monotherapy. In addition,
because of adverse effects (primarily myopathy), some
patients may be unwilling to use or unable to tolerate statin
therapy at all or may not tolerate a full therapeutic statin
dose. Also, statins may increase risk of new-onset diabetes
in patients at high risk for diabetes. Thus, there remains a
need for other lipid-lowering drugs to be used in combi-
nation with or in place of statins. The purpose of this article
is to review available data from the literature on the use of
colesevelam, a second-generation bile acid sequestrant, in
combination with other lipid-lowering agents. Colesevelam
has been studied in combination with statins, niacin,
fibrates, and ezetimibe (including some three-drug combi-
nations). An additive reduction in LDL-C was seen with all
combinations. Other observed effects of colesevelam in
combination with other lipid-lowering drugs include
reductions in apolipoprotein (apo) B (with statins, fibrates,
ezetimibe, statin plus niacin, or statin plus ezetimibe) and
high-sensitivity C-reactive protein (with statins), and
increases in apo A-I (with statins, ezetimibe, or statins plus
niacin). Triglyceride levels remained relatively unchanged
when colesevelam was combined with statins, fibrates,
ezetimibe, or statin plus ezetimibe, and decreased with the
triple combination of colesevelam, statin, and niacin.
Colesevelam offset the negative glycemic effects of statins
and niacin in subjects with insulin resistance or impaired
glucose tolerance. Colesevelam was generally well toler-
ated when added to other lipid-lowering therapies in clin-
ical trials, with gastrointestinal effects such as constipation
being the predominant adverse events. Since colesevelam
is not absorbed and works primarily in the intestine, it has a
low potential for systemic metabolic drug–drug interac-
tions with other drugs. Colesevelam has been shown to not
interact with the lipid-lowering drugs lovastatin and
fenofibrate; where interaction may be anticipated, sepa-
rating dosing times by 4 h reduces the impact of any
interaction. Available data confirms that colesevelam has
additive cholesterol-lowering effects when used in combi-
nation with other lipid-lowering therapies. Furthermore, in
some patient populations, the additional glucose-lowering
effect of colesevelam may be beneficial in offsetting
hyperglycemic effects of other lipid-lowering drugs.
1 Introduction
Patients with hyperlipidemia have an increased risk of
stroke, myocardial infarction, cardiovascular disease, and
other complications [1]. The Third Report of the National
Cholesterol Education Program Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol
in Adults (ATP-III) identified low-density lipoprotein
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cholesterol (LDL-C) as the primary target for cholesterol-
lowering therapy [1]. Based on ATP-III and a subsequent
update, LDL-C goals are defined as \160 mg/dL for
individuals with 0–1 risk factor, \130 mg/dL for those
with C2 risk factors, and \100 mg/dL for those with cor-
onary heart disease (CHD) or CHD risk equivalents, with
an optional goal of \70 mg/dL for those with both CHD
and additional risk factors [1, 2].
Prior to the advent of statins, bile acid sequestrants were
recommended as first-line therapy for lowering LDL-C
levels [3]. Early studies with cholestyramine and colestipol
showed reductions in total cholesterol [4–9] that were later
shown to be primarily attributable to reduced levels of
LDL-C [10]. The combination of bile acid sequestrants and
niacin was found to reduce LDL-C and increase high-
density lipoprotein cholesterol (HDL-C) levels [11, 12].
Importantly, a clinical trial with the bile acid sequestrant
cholestyramine, the Lipid Research Clinics Coronary Pri-
mary Prevention Trial, was the first to demonstrate that a
reduction in LDL-C levels (mean reduction 12 % vs. pla-
cebo) translated into a significant reduction in cardiovas-
cular risk over 7 years (19 % reduction in risk of CHD
death or nonfatal myocardial infarction; p \ 0.001) [13].
1.1 Statin Monotherapy: Strengths and Limitations
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A
reductase (statins) are considered first-line pharmacological
therapy for lowering LDL-C levels [1]. The West of
Scotland Coronary Prevention Study demonstrated that the
reduction in LDL-C with pravastatin (mean reduction 26 %
vs. no change with placebo) was accompanied by a sig-
nificant reduction in cardiovascular risk (31 % reduction in
risk of CHD death or nonfatal myocardial infarction;
p \ 0.001) over an average follow-up period of 4.9 years
among men with hypercholesterolemia and no history of
myocardial infarction [14]. A similar reduction in cardio-
vascular risk in the secondary prevention setting was
demonstrated by the Scandinavian Simvastatin Survival
Study; a reduction in LDL-C of 35 % (vs. ?1 % with
placebo) was accompanied by a 30 % reduction in total
mortality (p = 0.0003) and a 34 % reduction in risk of
major coronary events (p \ 0.00001) over a median of
5.4 years of follow-up [15]. Statins also reduce triglyceride
levels (7–30 %) and increase HDL-C levels (5–15 %) [1].
However, a substantial proportion of patients (up to
approximately 50 %) do not achieve LDL-C goals with
statin monotherapy [16–21]. Another consideration is that
some patients may be unwilling to use or unable to tolerate
statin therapy because of adverse effects. The most well-
known type of adverse effect associated with statin therapy
is myopathy, the effects of which can range in severity
from asymptomatic increases in creatine kinase, through
myalgias and muscle weakness, up to the rare but poten-
tially fatal rhabdomyolysis [22, 23]. Some patients may not
be able to tolerate maximal doses of statins, as adverse
effects associated with statin therapy are often dose related
[24, 25]. A meta-analysis of statin trials showed that the
use of intensive-dose statin therapy, compared with mod-
erate-dose therapy, was associated with a significant
increase in risk of any adverse event (odds ratio 1.44; 95 %
confidence interval [CI] 1.33–1.55; p \ 0.001) and risk of
adverse events leading to treatment discontinuation (1.28;
1.18–1.39; p \ 0.001) [26]. In the Study of the Effective-
ness of Additional Reductions in Cholesterol and Homo-
cysteine (SEARCH), patients with a history of myocardial
infarction receiving simvastatin 80 mg had an increased
risk of myopathy (0.9 vs. 0.03 %; relative risk 26.6, 95 %
CI 6.5–109.3; p \ 0.0001) and rhabdomyolysis (0.1 vs.
0.0 %) compared with patients taking simvastatin
20 mg/day [27]. Based on findings such as these, the US
Food and Drug Administration placed limitations on the
use of the 80-mg dose of simvastatin [23]. The results of
the Cholesterol Treatment Trialists’ meta-analysis pub-
lished in 2012 suggest that the present guidelines may need
to be reconsidered to include statin therapy for patients at
low risk of vascular disease, based on their observation that
the statin-associated benefit of a reduction in major vas-
cular events exceeded any known hazards of statin therapy
[28]. However, a recent retrospective cohort analysis by
Mansi et al. [29] concluded that further adverse event
studies are required, based on their finding that musculo-
skeletal conditions, arthropathies, injuries (dislocations,
strains, and sprains), and pain are more common in statin
users than in non-users. They concluded that ‘‘the full
spectrum of statins’ musculoskeletal adverse events may
not be fully explored, and further studies are warranted,
especially in physically active individuals’’ [29].
More recently, concerns have been raised with regard to
statins having unfavorable glycemic effects. A number of
studies have shown an increased risk of developing new-
onset diabetes associated with statin therapy [30–32],
particularly in individuals with multiple risk factors for
developing diabetes [33]. A dose effect has also been
shown for this increased risk with statins [31, 34]. In a
study in individuals at risk of developing type 2 diabetes
who were participating in lifestyle interventions, increased
fasting glucose levels were seen in statin users but not in
non-users [35]. Such findings have led to US labeling for
statins being updated to include warnings regarding
increased risk of elevated blood sugar levels. While short-
term cardiovascular benefit may outweigh long-term dia-
betes risk for many patients, for patients who are already at
risk of developing type 2 diabetes, clinicians may be
concerned about prescribing a lipid-lowering therapy that
may further increase diabetes risk.
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1.2 Combination Therapy
Combination therapy with other lipid-lowering agents has
the potential for additive reductions in LDL-C, although
additional cardiovascular benefit has not been demon-
strated. A meta-analysis indicated that the combination of
statins with fibrates or ezetimibe was not associated with
better clinical outcomes than high-dose statin mono-
therapy; limited outcomes data were available for combi-
nations of statins with other lipid-lowering agents [36].
Recent American Diabetes Association guidelines indicate
that combination lipid-lowering therapy is not broadly
recommended because of the lack of demonstrated incre-
mental cardiovascular benefit over that achieved with
statins [37]. Similarly, the current European Society of
Cardiology/European Atherosclerosis Society guidelines
for the management of dyslipidemia recommend consid-
ering combination therapy in high-risk individuals, those
with very high LDL-C levels, or in patients who are either
statin-intolerant or unable to tolerate higher statin doses
[38]. However, a systematic review of agents used to treat
dyslipidemias in clinical practice concluded that comple-
mentary effects of agents other than statins might sub-
stantially provide clinical benefits in not only individuals
with severe dyslipidemias but in other patients as well. The
author recommended that multiple drug combinations
should be more widely used to potentially get more people
to lipoprotein goals, even in light of the fact that cardio-
vascular outcomes data are lacking for such combination
therapies [39].
1.3 Purpose of this Review
Although statins have superseded bile acid sequestrants as
first-line lipid-lowering agents, bile acid sequestrants such
as the second-generation agent colesevelam can be used in
combination with a range of other classes of lipid-lowering
agents. The purpose of this article is to review available
data from the literature on the use of colesevelam in
combination with other lipid-lowering agents and report
the efficacy of these combination therapies in improving
the lipid profile as well as non-lipid parameters. The tol-
erability and safety of colesevelam in combination therapy
is also briefly discussed. Clinical outcomes data for
colesevelam, either as monotherapy or in combination with
other agents, were not included in this review, as the
literature search did not find any published outcomes data.
1.4 Methodology
This review is based on clinical trials reporting the lipid-
lowering effects of colesevelam used in dual or triple
combination with other lipid-lowering agents, including
statins, fibrates, niacin, and ezetimibe. Clinical study
publications were identified from MEDLINE literature
searches using the search terms ‘colesevelam’ and either
‘atorvastatin,’ ‘fluvastatin,’ ‘lovastatin,’ ‘pitavastatin,’
‘pravastatin,’ ‘simvastatin,’ ‘rosuvastatin,’ ‘gemfibrozil,’
‘fenofibrate,’ ‘clofibrate,’ ‘ezetimibe,’ ‘niacin,’ or ‘nico-
tinic acid.’ Studies reporting lipid-lowering efficacy results
were individually selected manually from the search results.
These search results included the lipid disorders hyper-
cholesterolemia, familial hypercholesterolemia, mixed
hyperlipidemia, and dyslipidemia, as well as the comor-
bidities diabetes, insulin resistance, and atherosclerosis.
2 Efficacy
2.1 Colesevelam in Dual Combinations
Studies evaluating colesevelam as part of a dual lipid-
lowering combination regimen have been conducted with
various statins, a fibrate, niacin, and ezetimibe.
2.1.1 Colesevelam Plus Statins
Colesevelam has been studied in combination with ator-
vastatin, lovastatin, rosuvastatin, and simvastatin in
patients with hypercholesterolemia. The combination of
colesevelam with a statin was more effective in lowering
LDL-C than the corresponding monotherapies (Fig. 1) [40–
42]. Notably, in a randomized, double-blind, placebo-
controlled, parallel-design, multicenter, 8-week study
evaluating the efficacy of colesevelam 3.75 g/day when
coadministered with atorvastatin 10 mg/day in 94 patients
with moderate hypercholesterolemia, the LDL-C reduction
achieved with colesevelam plus atorvastatin (48 %) was
not significantly different from that observed with atorva-
statin 80 mg/day (53 %) [41]. A prospective, randomized,
open-label, blinded endpoint study that assessed changes in
lipid profile as a secondary endpoint in 40 patients assigned
to colesevelam 3.75 g/day plus rosuvastatin 5 mg/day
combination therapy or rosuvastatin 10 mg/day mono-
therapy for 3 months showed that similar reductions in
LDL-C were also observed with colesevelam 3.75 g/day
plus rosuvastatin 5 mg/day and rosuvastatin 10 mg/day
alone in patients with hypercholesterolemia and insulin
resistance (-45 % for both) [43]. It should be noted that
the small sample size and open-label design were listed as
study limitations and could have potentially introduced
bias into the study’s findings.
The addition of colesevelam to existing statin therapy
has been shown to have an incremental benefit on LDL-C
levels. A pooled analysis of three randomized, double-
blind, placebo-controlled, parallel, 6-week clinical trials
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evaluated the efficacy of adding colesevelam 3.75 g/day or
placebo to stable existing statin therapy (atorvastatin,
pravastatin, or simvastatin) in 204 patients with primary
hypercholesterolemia. Study results showed a significant
incremental reduction in LDL-C with the addition of
colesevelam to statins (-9.2 %; p B 0.001) [44]. Simi-
larly, in a post hoc analysis of pooled data from three
double-blind, placebo-controlled studies in which
colesevelam 3.75 g/day or placebo was added to existing
metformin-, sulfonylurea-, or insulin-based therapy in
patients (N = 301, 437, and 280, respectively) with type 2
diabetes, among patients receiving statins at baseline, the
addition of colesevelam led to a significant reduction in
LDL-C (-15.6 %; p \ 0.0001) [45].
Levels of HDL-C significantly increased with both
colesevelam plus atorvastatin 10 mg/day and with atorva-
statin 80 mg/day alone, but the increase was numerically
greater for the combination (11 vs. 5 %). This may reflect a
paradoxical decrease in the effect on HDL-C at higher
doses of atorvastatin [41].
Changes in LDL-C were accompanied by reductions in
apolipoprotein (apo) B. Significant (p \ 0.05) reductions
from baseline in apo B were seen with colesevelam
monotherapy (-10 %), atorvastatin 10 mg/day (-32 %)
and 80 mg/day (-46 %), and colesevelam plus atorvastatin
10 mg/day (-38 %; p \ 0.05 for differences among
treatment groups) [41]. Similarly, in a multicenter, ran-
domized, double-blind, placebo-controlled trial to deter-
mine the lipid-lowering efficacy of colesevelam
coadministered with simvastatin in 251 patients with pri-
mary hypercholesterolemia, there was a significantly
greater reduction from baseline in apo B with colesevelam
plus simvastatin than with either agent as monotherapy
(-33 vs. -14 % and -20 %, respectively; p \ 0.05) [42].
Both dosing regimens of colesevelam plus lovastatin
achieved reductions in apo B (-24 % for both) that
exceeded those of the individual components (-3 and
-16 %, respectively) [40].
Increases in apo A-I were also observed with active
treatment [40–42]. In the atorvastatin study, significant
(p \ 0.05) increases from baseline in apo A-I were seen
only with colesevelam monotherapy (?4 %) and cole-
sevelam plus atorvastatin (?9 %); the differences among
treatment groups were also significant (p \ 0.0001) [41].
In the simvastatin study, significant increases from baseline
in apo A-I were seen with colesevelam alone (?4 %;
p \ 0.05), simvastatin alone (?5 %; p \ 0.05), and
Fig. 1 Percent reductions from baseline in low-density lipoprotein
cholesterol (LDL-C) in studies evaluating colesevelam (COL)
administered in combination with a statin: a COL and atorvastatin
(ATO) alone and in combination [41], b COL and lovastatin (LOV)
alone and in combination [40], and c COL and simvastatin (SIM)
alone and in combination [42]. ap \ 0.01 for all between-group
comparisons. bp \ 0.01 for all between-group comparisons except
COL ? ATO 10 mg/day vs. ATO 80 mg/day (p = 0.07). cp \ 0.05
vs. placebo. dp \ 0.05 vs. each monotherapy. ep \ 0.0001 vs.
placebo. fp B 0.001 vs. each monotherapy. gCOL and LOV given
together at dinner. hCOL given at dinner and LOV administered at
bedtime. ATO panel adapted from Hunninghake et al. [41], with
permission from Elsevier. LOV panel reproduced from Davidson
et al. [40], Copyright  2001 Wiley Periodicals, Inc., with permission
from John Wiley & Sons, Inc. SIM panel adapted from Knapp et al.
[42], with permission from Elsevier
b
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colesevelam plus simvastatin (?10 %; p \ 0.0001) [42].
Similarly, in the lovastatin study, increases in apo A-I were
significant with colesevelam alone (?8 %; p \ 0.0001),
lovastatin alone (?5 %; p \ 0.05), and colesevelam plus
lovastatin dosed together (?5 %; p \ 0.05), but did not
reach statistical significance with colesevelam plus lova-
statin dosed apart (?4 %) [40].
Triglyceride levels generally decreased from baseline
with statin monotherapies, increased with colesevelam
monotherapy, and remained relatively unchanged with the
combination of colesevelam and a statin [40–42], although
the reductions with statin monotherapy in the atorvastatin
study (atorvastatin 10 or 80 mg/day) led to a significant
difference compared with the colesevelam monotherapy
and colesevelam plus atorvastatin 10 mg/day groups
(p \ 0.05) [41]. Significant increases in triglyceride levels
were reported in patients with type 2 diabetes in two piv-
otal trials where colesevelam was added to either sulfo-
nylurea- or insulin-based therapy [46, 47]; however, in a
third pivotal diabetes trial, triglyceride levels were not
significantly increased when colesevelam was added to
metformin-based therapy [48].
Some non-lipid parameters also showed findings of
interest in these studies. In the pooled analysis of double-
blind, placebo-controlled trials of colesevelam 3.75 g/day
or placebo added to statin therapy, a significant median
reduction in high-sensitivity C-reactive protein levels was
seen with the addition of colesevelam (-23.3 %; p \ 0.01)
[44]. In addition, in the study of colesevelam 3.75 g/day
plus rosuvastatin 5 mg/day or rosuvastatin 10 mg/day
alone in patients with hypercholesterolemia and insulin
resistance, homeostasis model assessment of insulin resis-
tance index increased in the rosuvastatin monotherapy
group and decreased in the combination therapy group,
leading to a significant between-group difference (?15 vs.
-32 %; p \ 0.05).[43]
2.1.2 Colesevelam Plus Fibrates
The primary effects of fibrates include reduction of tri-
glycerides (20–50 %) and increases in HDL-C levels
(10–20 %); moderate increases in LDL-C (5–20 %) may
also be observed, but the effects vary depending on the
patient’s lipid profile [1, 49]. One study has evaluated the
dual combination of colesevelam and a fibrate.
This randomized, double-blind, placebo-controlled,
parallel-group study investigating the efficacy of fenofi-
brate plus colesevelam HCl versus fenofibrate mono-
therapy included a 4- to 8-week washout period followed
by an 8-week run-in period wherein 129 patients with
mixed hyperlipidemia were administered fenofibrate
160 mg/day. Patients were then randomized to receive
fenofibrate in combination with colesevelam 3.75 g/day or
placebo for 6 weeks [50]. Colesevelam plus fenofibrate
produced significantly greater reductions in LDL-C levels
than fenofibrate monotherapy from the end of the run-in
period to study end (-10.4 vs. ?2.3 %; p \ 0.0001);
effects on apo B were similar (-7.3 vs. ?0.8 %;
p = 0.0002). There was a slight increase in triglycerides in
the combination therapy group and a slight decrease in the
fenofibrate monotherapy group (?5.6 vs. -2.6 %), but
there was no significant difference between the groups
[50]. Similarly, HDL-C levels slightly increased in the
combination therapy group and slightly decreased in
the fenofibrate monotherapy group (?0.2 vs. -1.1 %;
p = 0.3854). Colesevelam and fenofibrate had additive
effects on LDL-C levels, regardless of whether patients’
triglyceride levels were [200 mg/dL. This is relevant for
patients with mixed hyperlipidemia, as those with triglyc-
eride levels [200 mg/dL often have unchanged or
increased LDL-C levels following initiation of fibrate or
niacin monotherapy, suggesting a need for treatments that
lower both LDL-C and triglyceride levels [50]. It should be
noted that colesevelam is contraindicated in patients with
triglyceride levels [500 mg/dL [51].
2.1.3 Colesevelam Plus Niacin
Niacin primarily increases HDL-C levels (15–35 %), and
to a lesser extent reduces triglycerides (20–50 %), with
moderate LDL-C-lowering effects (5–25 %) [1]. One
recent study evaluated the dual combination of coleseve-
lam and niacin. In the study, adults with dyslipidemia and
impaired fasting plasma glucose levels were randomized to
receive colesevelam 3.75 g/day (n = 70) or placebo in
addition to niacin (n = 70; titrated from 500 mg/day up to
a maximum of 2,000 mg/day, based on tolerability) for
12 weeks [52]. Significantly greater reductions in LDL-C
were seen with colesevelam compared with placebo (-20.7
vs. -12.9 %; p = 0.0088). In addition, colesevelam was
shown to offset the adverse effects of niacin on glucose
metabolism; subjects who received colesevelam had sig-
nificantly smaller increases in fasting plasma glucose (1.8
vs. 6.7 mg/dL; p = 0.0046) and hemoglobin A1c (0.06 vs.
0.18 %; p = 0.005) compared with those who received
placebo [52].
Although colesevelam/niacin combination therapy
demonstrated lipid-lowering and metabolic benefits versus
the placebo/niacin combination, results of the AIM-HIGH
and HPS2-THRIVE studies suggest that the use of niacin in
lipid-lowering combination therapy may be limited
[53, 54]. These studies demonstrated that the addition of
niacin to a statin had no incremental benefit in reducing
cardiovascular events (AIM-HIGH) or the risk of heart
attacks, strokes, or operations to open blocked arteries
(HPS2-THRIVE) in patients with well-controlled LDL-C
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levels. Furthermore, the unwanted side effects associated
with the addition of niacin appeared to outweigh the ben-
efits of its use [53, 54].
2.1.4 Colesevelam Plus Ezetimibe
Ezetimibe primarily reduces LDL-C levels (*19 %), with
more modest reductions in triglycerides (*8 %) and
increases in HDL-C (3 %) in patients with primary (het-
erozygous familial and non-familial) hypercholesterolemia,
as shown by Pandor et al. [55] in a systematic review and
meta-analysis of randomized controlled trials comprising
2,722 patients administered ezetimibe monotherapy for a
minimum treatment period of 12 weeks. As this was a
meta-analysis, the authors noted that although there was no
statistical evidence of significant heterogeneity in the
assessed trials, differences in patient characteristics or the
trial designs between the studies could have potentially
influenced the results [55]. Limited studies have been
conducted with the dual combination of colesevelam and
ezetimibe. A small, double-blind, randomized, parallel-
design pilot study in adults with hypercholesterolemia
(N = 20) indicated that the incremental LDL-C-lowering
effects of adding colesevelam 1.875 g/day to ezetimibe
10 mg/day for 12 weeks was not statistically significant
(-30 vs. -24 %; p = 0.102) [56]. The small number of
patients in this study and the lack of assurance that patients
in the two treatment groups did not differ in some respects
were listed as relevant study limitations [56].
However, in a larger multicenter, randomized, double-
blind, placebo-controlled, parallel-group study in 86
adults with primary hypercholesterolemia that was
designed to determine the superiority of colesevelam
3.75 g/day plus ezetimibe 10 mg/day versus ezetimibe
alone, a significantly greater reduction in LDL-C was
seen with colesevelam plus ezetimibe, compared with
ezetimibe monotherapy, for 6 weeks (-32.3 vs. -21.4 %;
p \ 0.0001) [57]. In addition, subjects receiving coles-
evelam plus ezetimibe, compared with ezetimibe mono-
therapy, had a significantly greater reduction in apo B
(-22.7 vs. -14.8 %; p = 0.0001) and increase in apo A-I
(?6.7 vs. ?1.3 %; p = 0.0036). There was a slight
increase in triglycerides in the combination therapy group
and a slight decrease in the ezetimibe monotherapy group
(?4.9 vs. -2.8 %), but there was no significant difference
between the groups [57]. Thus, it is possible to achieve
LDL-C reductions with this combination that are similar
to those seen with low-dose statin monotherapy. A limi-
tation of this study was that levels of ezetimibe were not
calculated. Consequently, the study could not assess if
colesevelam had an effect on ezetimibe absorption [57].
However, it is noteworthy that the two agents were not
coadministered, i.e., ezetimibe was administered at bed-
time whereas three tablets of colesevelam were taken with
each morning and evening meal or six tablets with the
evening meal.
2.2 Colesevelam in Triple Combinations
Two studies have evaluated the efficacy of colesevelam-
based, triple-drug combination lipid-lowering regimens. A
randomized, double-blind, partially placebo-controlled,
1-year study in adults with atherosclerotic disease and
dyslipidemia (N = 123) evaluated the incremental effects
of adding extended-release niacin (titrated from 500 mg/
day to 2 g/day) and colesevelam 3.75 g/day to atorvastatin
10–80 mg/day [58]. Compared with atorvastatin mono-
therapy, there was no further reduction in LDL-C with
atorvastatin plus niacin (-47 % for both), but a signifi-
cantly greater reduction was achieved with atorvastatin
plus niacin plus colesevelam (-57 %; p = 0.001); a lower
average atorvastatin dose was required to meet LDL-C
targets with dual and triple therapy. In addition, the triple-
combination group, compared with the atorvastatin
monotherapy group, had significantly greater reductions in
apo B (-51 vs. -40 %; p \ 0.01) and triglycerides (-42
vs. -25 %; p \ 0.01) and a significantly greater increase in
apo A-I (?15 vs. ?7 %; p = 0.01). Changes in apo B
(-45 %), triglycerides (-33 %), and apo A-I (?11 %) in
the dual-combination group were not significantly different
from those in the atorvastatin monotherapy group [58].
The addition of colesevelam to stable, maximally tol-
erated therapy with a statin plus ezetimibe for 12 weeks in
adults with familial hypercholesterolemia resulted in sig-
nificantly greater reductions in LDL-C (-11.4 vs. ?0.6 %;
p \ 0.001) and apo B (-6.0 vs. ?4.6 %; p = 0.01) com-
pared with placebo [59]. Triglyceride levels increased in
both groups, resulting in no significant between-group
difference. An unexpected finding was that hemoglobin
A1c was significantly reduced in patients receiving coles-
evelam as compared with placebo (least-squares mean
treatment difference -0.12 %; p \ 0.05). The patients’
mean baseline hemoglobin A1c of 5.7–5.8 % suggests that
many were at high risk for development of new-onset type
2 diabetes [59].
3 Safety and Tolerability
Colesevelam, which is not systemically absorbed, was
generally well tolerated when added to other lipid-lowering
therapies [40–42, 50, 57, 59]. Adverse event profiles were
similar to the comparators, apart from a slight increase in
gastrointestinal adverse events such as constipation in
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some studies [40, 50, 57, 59]. Statistical significance was
assessed and showed no differences in the incidence of
constipation in the lovastatin combination study (placebo,
4 %; colesevelam monotherapy, 10 %; lovastatin mono-
therapy, 0 %; colesevelam plus lovastatin dosed together,
7 %; colesevelam plus lovastatin dosed apart, 4 %) [40],
and the study assessing the triple combination of coles-
evelam, ezetimibe, and a statin (colesevelam, 9 %; pla-
cebo, 5 %) [59].
Colesevelam has a low propensity for drug–drug inter-
actions, and those that occur can typically be minimized by
staggering drug administration by 4 h [60–63]. Notably,
although drug–drug interactions with a number of lipid-
lowering therapies (including simvastatin, fluvastatin,
gemfibrozil, and ezetimibe) have been reported with the
first-generation bile acid sequestrants [64–67], colesevelam
has been shown to have no pharmacokinetic drug–drug
interactions with lovastatin or fenofibrate [68, 69].
It should be noted that the colesevelam prescribing
information states that the use of colesevelam is contrain-
dicated in patients with triglyceride levels [500 mg/dL,
and that colesevelam should be discontinued if triglycer-
ides exceed 500 mg/dL or if the patient develops hyper-
triglyceridemia-induced pancreatitis [51].
4 Conclusions
Colesevelam has additive cholesterol-lowering effects
when used in combination with other lipid-lowering ther-
apies. This is relevant to not only patients who are resistant
or intolerant to statins, but also patients with mixed
hyperlipidemia. In some patient populations, the additional
glucose-lowering effect of colesevelam may be beneficial
in offsetting hyperglycemic effects of other lipid-lowering
drugs. The effect of colesevelam on cardiovascular mor-
bidity and mortality has not been established. Colesevelam
is generally well tolerated, with a low potential for sys-
temic metabolic drug–drug interactions. More research is
needed with combination therapy, including combinations
with colesevelam.
Acknowledgments Sushma Soni of inScience Communications,
Springer Healthcare, provided medical writing support funded by
Daiichi Sankyo, Inc. Oliseyenum M. Nwose, MBBS, MRCPath, is
employed by Daiichi Sankyo, Inc., and Michael R. Jones, PhD, was
previously employed by Daiichi Sankyo, Inc. All authors provided
scientific interpretation of the data, provided substantive contributions
to the manuscript, and approved the final draft of the submission.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
References
1. National Cholesterol Education Program Expert Panel on
Detection, Evaluation and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III). Third Report of the
National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III) final report. Circulation.
2002;106(25):3143–421.
2. Grundy SM, Cleeman JI, Merz CNB, Brewer HB Jr, Clark LT,
Hunninghake DB, et al; for the Coordinating Committee of the
National Cholesterol Education Program. Implications of recent
clinical trials for the National Cholesterol Education Program
Adult Treatment Panel III guidelines. Circulation. 2004;110(2):
227–39.
3. Goodman DS, Hulley SB, Clark LT, Davis CE, Fuster V, LaRosa
JC, et al. Report of the National Cholesterol Education Program
Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults. Arch Intern Med. 1988;148(1):36–69.
4. Gherondache CN, Pincus G. Metabolic changes induced in
elderly patients with a cholesterol lowering resin, cholestyramine.
Metabolism. 1964;13:1462–8.
5. Hashim SA, Vanitallie TB. Cholestyramine resin therapy for
hypercholesteremia: clinical and metabolic studies. JAMA.
1965;192:289–93.
6. Casdorph HR. Hypercholesteremia—treatment with cholestyr-
amine, a bile acid sequestering resin. Calif Med. 1967;106(4):
293–5.
7. Glueck CJ, Ford S, Scheel D, Steiner P. Colestipol and chole-
styramine resin. Comparative effects in familial type II hyper-
lipoproteinemia. JAMA. 1972;222:676–81.
8. Ryan JR, Jain A. The effect of colestipol or cholestyramine on
serum cholesterol and triglycerides in a long-term controlled
study. J Clin Pharmacol New Drugs. 1972;12(7):268–73.
9. Parkinson TM, Gundersen K, Nelson NA. Effects of colestipol
(U-26,597A), a new bile acid sequestrant, on serum lipids in
experimental animals and man. Atherosclerosis. 1970;11(3):
531–7.
10. Lipid Research Clinics Program. The Lipid Research Clinics
Coronary Primary Prevention Trial results. I. Reduction in inci-
dence of coronary heart disease. JAMA. 1984;251(3):351–64.
11. Angelin B, Eriksson M, Einarsson K. Combined treatment with
cholestyramine and nicotinic acid in heterozygous familial hy-
percholesterolaemia: effects on biliary lipid composition. Eur J
Clin Invest. 1986;16(5):391–6.
12. Kane JP, Malloy MJ, Tun P, Phillips NR, Freedman DD, Wil-
liams ML, et al. Normalization of low-density-lipoprotein levels
in heterozygous familial hypercholesterolemia with a combined
drug regimen. N Engl J Med. 1981;304(5):251–8.
13. Lipid Research Clinics Program. The Lipid Research Clinics
Coronary Primary Prevention Trial results. II. The relationship of
reduction in incidence of coronary heart disease to cholesterol
lowering. JAMA. 1984;251(3):365–74.
14. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfar-
lane PW, for the West of Scotland Coronary Prevention Study
Group, et al. Prevention of coronary heart disease with prava-
statin in men with hypercholesterolemia. N Engl J Med.
1995;333(20):1301–7.
15. Scandinavian Simvastatin Survival Study Group. Randomised
trial of cholesterol lowering in 4444 patients with coronary heart
disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet. 1994;344(8934):1383–9.
16. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment
Assessment Project (L-TAP): a multicenter survey to evaluate the
Bile Acid Sequestrant-Based Combination Therapy 321
percentages of dyslipidemic patients receiving lipid-lowering
therapy and achieving low-density lipoprotein cholesterol goals.
Arch Intern Med. 2000;160(4):459–67.
17. Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H,
The Vascular Protection (VP) and Guidelines Oriented Approach
to Lipid Lowering (GOALL) Registries Investigators, et al.
Contemporary management of dyslipidemia in high-risk patients:
targets still not met. Am J Med. 2006;119(8):676–83.
18. Bo _zentowicz-Wikarek M, Kocełak P, Smertka M, Olszanecka-
Glinianowicz M, Chudek J. Effectiveness of lipid-lowering
therapy with statins for secondary prevention of atherosclerosis—
guidelines vs. reality. Pharmacol Rep. 2012;64(2):377–85.
19. Robinson JG, Ballantyne CM, Hsueh W, Rosen J, Lin J, Shah A,
et al. Achievement of specified low-density lipoprotein choles-
terol, non-high-density lipoprotein cholesterol apolipoprotein B,
and high-sensitivity C-reactive protein levels with ezetimibe/
simvastatin or atorvastatin in metabolic syndrome patients with
and without atherosclerotic vascular disease (from the VYMET
study). J Clin Lipidol. 2011;5(6):474–82.
20. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyo¨ra¨la¨ K,
Keil U, for the EUROASPIRE Study Group, et al. Cardiovascular
prevention guidelines in daily practice: a comparison of
EUROASPIRE I, II, and III surveys in eight European countries.
Lancet. 2009;373(9667):929–40.
21. Kotseva K, Wood D, De Backer G, EUROASPIRE Study Group,
et al. EUROASPIRE III. Management of cardiovascular risk
factors in asymptomatic high-risk patients in general practice:
cross-sectional survey in 12 European countries. Eur J Cardiovasc
Prev Rehabil. 2010;17(5):530–40.
22. Mammen AL, Amato AA. Statin myopathy: a review of recent
progress. Curr Opin Rheumatol. 2010;22(6):644–50.
23. Egan A, Colman E. Weighing the benefits of high-dose simva-
statin against the risk of myopathy. N Engl J Med. 2011;
365(4):285–7.
24. Golomb BA, Evans MA. Statin adverse effects: a review of the
literature and evidence for a mitochondrial mechanism. Am J
Cardiovasc Drugs. 2008;8(6):373–418.
25. Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associ-
ated muscle-related adverse effects: a case series of 354 patients.
Pharmacotherapy. 2010;30(6):541–53.
26. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy
M, et al. Meta-analysis of drug-induced adverse events associated
with intensive-dose statin therapy. Clin Ther. 2007;29(2):253–60.
27. Study of the Effectiveness of Additional Reductions in Choles-
terol Homocysteine Collaborative Group. Intensive lowering of
LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12
064 survivors of myocardial infarction: a double-blind random-
ised trial. Lancet. 2010;376(9753):1658–69.
28. Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects
of lowering LDL cholesterol with statin therapy in people at low
risk of vascular disease: meta-analysis of individual data from 27
randomised trials. Lancet. 2012;380(9841):581–90.
29. Mansi I, Frei CR, Pugh MJ, Makris U, Mortensen EM. Statins
and musculoskeletal conditions, arthropathies, and injuries
[published online ahead of print June 3, 2013]. JAMA Intern
Med. doi:10.1001/jamainternmed.2013.6184.
30. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen
AJM, et al. Statins and risk of incident diabetes: a collaborative
meta-analysis of randomised statin trials. Lancet. 2010;
375(9716):735–42.
31. Zaharan NL, Williams D, Bennett K. Statins and risk of treated
incident diabetes in a primary care population. Br J Clin Phar-
macol. 2013;75(4):1118–24.
32. Danaei G, Garcı´a Rodrı´guez LA, Fernandez Cantero O, Herna´n
MA. Statins and risk of diabetes: an analysis of electronic
medical records to evaluate possible bias due to differential
survival. Diabetes Care. 2013;36(5):1236–40.
33. Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJP,
Messig M, et al. Cardiovascular event reduction versus new-onset
diabetes during atorvastatin therapy: effect of baseline risk fac-
tors for diabetes. J Am Coll Cardiol. 2013;61(2):148–52.
34. Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters
DD, et al. Risk of incident diabetes with intensive-dose compared
with moderate-dose statin therapy: a meta-analysis. JAMA.
2011;305(24):2556–64.
35. Rautio N, Jokelainen J, Oksa H, Saaristo T, Peltonen M, Vanhala
M, et al. Do statins interfere with lifestyle intervention in the
prevention of diabetes in primary healthcare? One-year follow-up
of the FIN-D2D project. BMJ Open. 2012;2(5):e001472.
36. Sharma M, Ansari MT, Abou-Setta AM, Soares-Weiser K, Ooi
TC, Sears M, et al. Systematic review: comparative effectiveness
and harms of combination therapy and monotherapy for dysli-
pidemia. Ann Intern Med. 2009;151(9):622–30.
37. American Diabetes Association. Standards of medical care in
diabetes—2013. Diabetes Care. 2013;36(Suppl 1):S11–66.
38. Reiner Zˇ, Catapano AL, De Backer G, et al. ESC/EAS guidelines
for the management of dyslipidaemias. The Task Force for the
management of dyslipidaemias of the European Society of Car-
diology (ESC) and the European Atherosclerosis Society (EAS).
Eur Heart J. 2011;32:1769–818.
39. Reiner Zˇ. Combined therapy in the treatment of dyslipidemia.
Fundam Clin Pharmacol. 2010;24(1):19–28.
40. Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D,
Isaacsohn J, et al. Low-dose combination therapy with cole-
sevelam hydrochloride and lovastatin effectively decreases low-
density lipoprotein cholesterol in patients with primary hyper-
cholesterolemia. Clin Cardiol. 2001;24(6):467–74.
41. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM,
Burke SK. Coadministration of colesevelam hydrochloride with
atorvastatin lowers LDL cholesterol additively. Atherosclerosis.
2001;158(2):407–16.
42. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM,
et al. Efficacy and safety of combination simvastatin and
colesevelam in patients with primary hypercholesterolemia. Am J
Med. 2001;110(5):352–60.
43. Florentin M, Liberopoulos EN, Rizos CV, Kei AA, Liamis G,
Kostapanos MS, et al. Colesevelam plus rosuvastatin 5 mg/day
versus rosuvastatin 10 mg/day alone on markers of insulin
resistance in patients with hypercholesterolemia and impaired
fasting glucose. Metab Syndr Relat Disord. 2013;11(3):152–6.
44. Bays HE, Davidson M, Jones MR, Abby SL. Effects of cole-
sevelam hydrochloride on low-density lipoprotein cholesterol and
high-sensitivity C-reactive protein when added to statins in
patients with hypercholesterolemia. Am J Cardiol. 2006;97(8):
1198–205.
45. Jialal I, Abby SL, Misir S, Nagendran S. Concomitant reduction
in low-density lipoprotein cholesterol and glycated hemoglobin
with colesevelam hydrochloride in patients with type 2 diabetes:
a pooled analysis. Metab Syndr Relat Disord. 2009;7(3):255–8.
46. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR.
Colesevelam HCl improves glycemic control and reduces LDL
cholesterol in patients with inadequately controlled type 2 dia-
betes on sulfonylurea-based therapy. Diabetes Care. 2008;31(8):
1479–84.
47. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and
safety of colesevelam in patients with type 2 diabetes mellitus
and inadequate glycemic control receiving insulin-based therapy.
Arch Intern Med. 2008;168(14):1531–40.
48. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam
hydrochloride therapy in patients with type 2 diabetes mellitus
322 M. R. Jones, O. M. Nwose
treated with metformin: glucose and lipid effects. Arch Intern
Med. 2008;168(18):1975–83.
49. Chapman MJ. Fibrates: therapeutic review. Br J Diabetes Vasc
Dis. 2006;6(1):11–20.
50. McKenney J, Jones M, Abby S. Safety and efficacy of cole-
sevelam hydrochloride in combination with fenofibrate for the
treatment of mixed hyperlipidemia. Curr Med Res Opin.
2005;21(9):1403–12.
51. Welchol [package insert]. Parsippany, NJ: Daiichi-Sankyo, Inc.;
2013.
52. Davidson MH, Rooney M, Pollock EM, Drucker JL, Choy Y. The
effect of colesevelam and niacin on low-density lipoprotein
cholesterol and plasma glucose (abstr.). Circulation. 2012;126(21
Suppl):A11700.
53. The AIM-HIGH Investigators. Niacin in patients with low HDL
cholesterol levels receiving intensive statin therapy. N Engl J
Med. 2011;365(24):2255–67.
54. HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of
Vascular Events). http://www.thrivestudy.org. Accessed 21 June
2013.
55. Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A,
et al. Ezetimibe monotherapy for cholesterol lowering in 2,722
people: systematic review and meta-analysis of randomized
controlled trials. J Intern Med. 2009;265(5):568–80.
56. Knopp RH, Tsunehara C, Retzlaff BM, Fish B, Nguyen H,
Anderson S, et al. Lipoprotein effects of combined ezetimibe and
colesevelam hydrochloride versus ezetimibe alone in hypercho-
lesterolemic subjects: a pilot study. Metabolism. 2006;55(12):
1697–703.
57. Bays H, Rhyne J, Abby S, Lai Y-L, Jones M. Lipid-lowering
effects of colesevelam HCl in combination with ezetimibe. Curr
Med Res Opin. 2006;22(11):2191–200.
58. Moore A, Phan BAP, Challender C, Williamson J, Marcovina S,
Zhao X-Q. Effects of adding extended-release niacin and cole-
sevelam to statin therapy on lipid levels in subjects with ath-
erosclerotic disease. J Clin Lipidol. 2007;1(6):620–5.
59. Huijgen R, Abbink EJ, Bruckert E, Stalenhoef AFH, Imholz
BPM, Durrington PN, for the Triple Study Group, et al. Cole-
sevelam added to combination therapy with a statin and ezetimibe
in patients with familial hypercholesterolemia: a 12-week,
multicenter, randomized, double-blind, controlled trial. Clin
Ther. 2010;32(4):615–25.
60. Brown KS, Armstrong IC, Wang A, Walker JR, Noveck RJ,
Swearingen D, et al. Effect of the bile acid sequestrant cole-
sevelam on the pharmacokinetics of pioglitazone, repaglinide,
estrogen estradiol, norethindrone, levothyroxine, and glyburide.
J Clin Pharmacol. 2010;50(5):554–65.
61. Donovan JM, Stypinski D, Stiles MR, Olson TA, Burke SK. Drug
interactions with colesevelam hydrochloride, a novel, potent
lipid-lowering agent. Cardiovasc Drugs Ther. 2000;14(6):
681–90.
62. Wickremasingha P, He L, Lee J, Tao B, Mendell-Harary J,
Walker J, et al. Lack of effect of colesevelam HCl on the single-
dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin,
rosiglitazone, and sitagliptin. Parsippany, NJ: Daiichi Sankyo,
Inc., 2013. (Data on file).
63. He L, Wickremasingha P, Lee J, Tao B, Mendell-Harary J,
Walker J, et al. The effects of colesevelam HCl on the single-dose
pharmacokinetics of glimepiride, extended-release glipizide, and
olmesartan medoxomil. Parsippany, NJ: Daiichi Sankyo, Inc.,
2013. (Data on file).
64. Nakai A, Nishikata M, Matsuyama K, Ichikawa M. Drug inter-
action between simvastatin and cholestyramine in vitro and
in vivo. Biol Pharm Bull. 1996;19(9):1231–3.
65. Kosoglou T, Statkevich P, Reyderman L, Pember LJC, Maxwell
SE, Courtney R, et al. Effects of selected drugs on exposure to
ezetimibe (abstr.). Eur Heart J. 2003;24(suppl):462.
66. Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson
WT. Pharmacokinetics of fluvastatin and specific drug interac-
tions. Am J Hypertens. 1993;6(11 Pt 2):375S–82S.
67. Forland SC, Feng Y, Cutler RE. Apparent reduced absorption of
gemfibrozil when given with colestipol. J Clin Pharmacol.
1990;30(1):29–32.
68. Donovan JM, Kisicki JC, Stiles MR, Tracewell WG, Burke SK.
Effect of colesevelam on lovastatin pharmacokinetics. Ann
Pharmacother. 2002;36(3):392–7.
69. Jones MR, Baker BA, Mathew P. Effect of colesevelam HCl on
single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet.
2004;43(13):943–50.
Bile Acid Sequestrant-Based Combination Therapy 323
